Illumina (ILMN)
(Delayed Data from NSDQ)
$139.02 USD
+10.04 (7.78%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $139.40 +0.38 (0.27%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$139.02 USD
+10.04 (7.78%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $139.40 +0.38 (0.27%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
Insulet's (PODD) Omnipod DASH System Now ISO 27001 Certified
by Zacks Equity Research
Insulet (PODD) is now the only insulin pump company to be awarded with both the ISO 27001 and the DTSec Cybersecurity Standard for Connected Diabetes Device Security certifications.
Boston Scientific's (BSX) $4.2B Buyout to Augment PI Business
by Zacks Equity Research
Boston Scientific (BSX) continues to expand on the back of its inorganic growth strategy. The latest takeover is expected to boost the PI business.
Bet on 5 Stocks With Strong Earnings Beat Potential
by Sanghamitra Saha
Inside the top-ranked stocks that can beat earnings estimates in their next releases.
Medtronic (MDT) Tops Q2 Earnings on Strong Segmental Growth
by Zacks Equity Research
Medtronic (MDT) demonstrated improved performances at CER on growth in all business segments. However, costs continue to escalate.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
llumina (ILMN) set to take over peer in a $1.2-billion deal, which will strengthen its position in the genomics market.
Pacific Biosciences Offers Insights on Aedes aegypti Genome
by Zacks Equity Research
Pacific Biosciences (PACB) uses its flagship Single Molecule, Real-Time technology to sequence the highest quality genome assembly for the Aedes aegypti mosquito.
Illumina (ILMN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed the most recent trading day at $308.23, moving -0.95% from the previous trading session.
Is Illumina (ILMN) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Illumina (ILMN).
The Zacks Analyst Blog Highlights: DXP Enterprises, Bristol-Myers Squibb, EnPro Industries, Illumina and NetApp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DXP Enterprises, Bristol-Myers Squibb, EnPro Industries, Illumina and NetApp
Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ILMN) Outperforming Other Medical Stocks This Year?
Wall Street Likely to Sustain Post-Midterm Rally: 5 Picks
by Nalak Das
Investors' optimism has been revived on risky assets like equities with a divided U.S. Congress.
Pacific Biosciences (PACB) Reports Q3 Loss, Revenues Fall Y/Y
by Zacks Equity Research
Pacific Biosciences (PACB) is getting acquired by Illumina (ILMN) by mid-2019.
Illumina (ILMN) Inks $1.2B Deal to Buy Pacific Biosciences
by Zacks Equity Research
Illumina (ILMN) taking out on its peer, in the $1.2-billion acquisition deal, will further strengthen the position of the former in the genomics market.
Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed at $322.73 in the latest trading session, marking a -0.43% move from the prior day.
Zacks.com highlights: Illumina, Molina Healthcare, Twitter, Vocera Communications and WNS Holdings
by Zacks Equity Research
Zacks.com highlights: Illumina, Molina Healthcare, Twitter, Vocera Communications and WNS Holdings
Go Beyond Earnings Growth, Bet on Beat With 5 Stocks
by Sanghamitra Saha
These top-ranked stocks are likely to beat on bottom line in their next releases.
Illumina (ILMN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Illumina (ILMN) closed at $292.25, marking a -0.97% move from the previous day.
The Zacks Analyst Blog Highlights: Procter & Gamble, Philip Morris, Honeywell, Lockheed and Illumina
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, Philip Morris, Honeywell, Lockheed and Illumina
Illumina (ILMN) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Illumina (ILMN) gains on strong consumables growth across its sequencing portfolio with strength in all throughput categories and microarray business in Q3.
Top Analyst Reports for Procter & Gamble, Philip Morris & Honeywell
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Philip Morris (PM) and Honeywell (HON).
Illumina (ILMN) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of 21.60% and 3.39%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ILMN) Outperforming Other Medical Stocks This Year?
Why Illumina (ILMN) Might Surprise This Earnings Season
by Zacks Equity Research
Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
AMGN or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMGN vs. ILMN: Which Stock Is the Better Value Option?
Pacific Biosciences Introduces Enhancements to Sequel System
by Zacks Equity Research
The latest enhancements in Pacific Biosciences??? (PACB) Sequel System represent strong improvement in terms of read length, throughput and accuracy in DNA sequencing.